Medical device CRO Genae buys health data management company

data infographic
Medical device CRO Genae has bought Hilbert Paradox (HPX) to strengthen its recently launched data management platform. (Pixabay)

Belgium-headquartered medical device CRO Genae has bought Hilbert Paradox (HPX) to strengthen its data management platform.

HPX’s solution uses computing power, data analytics and artificial intelligence to help collect, store and analyze health data. It also helps clients examine and increase the value of their health datasets—an ability known as data equity—for better patient treatments.

HPX’s services will be folded into Genae’s digital health division and incorporated into its Staicy platform.

Genae launched its health data management system Staicy last September. Based on Genae’s two-decade experience in electronic data capture and its clinical research expertise gathered from about 450 clinical trials, Staicy supports data management through analysis, visualization and correlation of a variety of data.

“It enables integration of otherwise isolated data silos and eClinical systems, such as CTMS platforms, ePRO and hospital files,” said Genae CEO Bart Segers at the time.

“Staicy is all about visual data discovery for clinical research, and HPX’s technology revolves around the same for digital health data,” Segers told FierceCRO.  

Sergers said the HPX technology is able to process large data volumes from connected and diagnostic devices, websites and applications in the field of genomics, biosensors and wearables.

“The rationale for integrating technology like the one from HPX is captured in future preventive requirements; moving from disease to health management in which the patient decides about what to share with whom,” he said.

Suggested Articles

Medtronic has expanded its portfolio aimed at improving the safety of head and neck surgeries, with a new acquisition and an FDA clearance.

By casting a broad, digital net to pick up the signs of coronavirus outbreaks, researchers hope to build an early warning system from wearable tech.

C2N Diagnostics launched a blood test that can identify the state of amyloid plaque in the brain, one of the hallmarks of Alzheimer's disease.